Part 1: The Paradigm Shift in Treating Dry Eye

In part one of a two–part series, Josh Johnston, OD discusses the paradigm shift in treating patients with dry eye.

Treating dry eye disease (DED) has truly evolved over the past years, and even more so recently with new diagnostics, therapies and FDA-approved drugs. We all know DED is progressive and can be hard to treat, which is actually one of the reasons I like it so much. It’s an exciting time for those of us treating DED. The paradigm shift has changed and there are new, novel products and therapies at our disposal that allow us to provide better options to patients and improve clinical outcomes.

The Dangers of Beauty Treatments

We all know using makeup, and particularly not removing it at night, can have a huge impact on eye health and lead to or worsen conditions such as blepharitis, Demodex and also dry eye. As such, it’s becoming increasingly important to discuss cosmetics and ocular hygiene with our patients. A recent case also highlights the dangers of beauty procedures, which are becoming increasingly popular, in this case eye lash tinting.

Optimizing the Ocular Surface Prior to Surgery: Why I Added Prokera to My Refractive Cataract Pre-Surgical Regimen

Refractive cataract surgery requires a high level of attention to the ocular surface. Patients expect perfect outcomes, and any compromise of the ocular surface interferes with preoperative measurements and proper IOL selection. To ensure we don’t end up with a postoperative refractive surprise, we need to be on alert for ocular surface disease and get it under control before proceeding with surgery.

Be Proactive

Our typical cataract surgery patients have all the risk factors for ocular surface problems. They have chronic disease comorbidities, they’re using multiple medications, and so forth. Many are neurotrophic to some degree; therefore, we can’t rely on them to report symptoms. We must proactively look for dry eye as well as epithelial-based diseases, such as Salzmann’s nodular degeneration (SND) and epithelial basement membrane dystrophy (EBMD). EBMD not only leads to irregularities in preoperative measurements and outcomes but also puts patients at risk for epithelial sloughing during surgery and poor wound healing postoperatively.

How to Maintain Patient Vision During Treatment for Ocular Surface Diseases

For the millions of Americans who suffer from symptoms of chronic ocular surface disease, traditional treatments typically provide only temporary relief for patients, primarily because they don’t tackle the corneal damage that may be causing the symptoms. At Bio-Tissue, we strive to continually research and develop groundbreaking regenerative medicine treatments to help these patients and improve their quality of life.

Our innovative PROKERA® products are the only FDA-cleared therapeutic medical devices that reduce inflammation and promote healing in order to rejuvenate and heal the cornea, which is essential for patients to find true relief. PROKERA is clinically proven and has helped more than 50,000 patients worldwide.